Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 11,177 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohort study Clear all

Conditions: Advanced Solid Tumors
Interventions: U3-1287 (AMG888); Drug
Lead sponsor: U3 Pharma GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more

Conditions: Conversion Disorder
Interventions: Standard of Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML
Interventions: LP-108, LP-108 and azacitidine; Drug
Lead sponsor: Newave Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Haematological Malignancies
Interventions: AS703569; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Nelarabine, Etoposide, Cyclophosphamide, Methotrexate, Filgrastim; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 26
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 22 more

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Chronic Kidney Disease, Anemia
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 35
States / cities: Mobile, Alabama • Pine Bluff, Arkansas • Azusa, California + 32 more

Conditions: Advanced Cancers
Interventions: MABp1; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Anti-OX40 Antibody BMS 986178, TLR9 Agonist SD-101; Biological · Drug
Lead sponsor: Ronald Levy; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Focal Segmental Glomerulosclerosis (FSGS)
Interventions: PF-06730512; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Geographic Atrophy
Interventions: PEGCETACOPLAN (APL-2); Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Bakersfield, California • Beverly Hills, California • Encino, California + 2 more

Conditions: Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable, Intravascular Large B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab, Vincristine Sulfate; Drug · Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Virus Quadrivalent Inactivated Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 15 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Malaria, Falciparum
Interventions: FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Diabetic Foot Ulcer
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers
Interventions: MK-3475; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 7
States / cities: Stanford, California • Baltimore, Maryland • Bethesda, Maryland + 4 more

Conditions: Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis (PsO)
Interventions: Deucravacitinib, Other systemic treatments for PsO; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
Interventions: BAL0891, Tislelizumab, Paclitaxel; Drug · Combination Product
Lead sponsor: SillaJen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 11
States / cities: New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more

Conditions: Acute Myeloid Leukemia
Interventions: Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 20 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee

Conditions: BAG3 Mutation Associated Dilated Cardiomyopathy
Interventions: ALXN2350; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 7
States / cities: Birmingham, Alabama • Palo Alto, California • Boston, Massachusetts + 4 more

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Zanubrutinib; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 24
States / cities: Aurora, Colorado • Newark, Delaware • Fort Myers, Florida + 21 more

Conditions: Healthy Volunteers
Interventions: AEF0117, Placebo; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Acute Myeloid Leukemia
Interventions: Emerfetamab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Birmingham, Alabama • Duarte, California • Houston, Texas + 1 more

Search by objective public record fields.

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

A First in Man Study of MABp1 in Patients With Advanced Cancers

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Development of Childhood Anti-Influenza Immunity

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

Autologous Polyclonal Tregs for Lupus

A Study to Assess Deucravacitinib Safety in Pregnancy

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)